People with diabetes often have low levels of the GLP-1 hormone. Some small studies, they note, have suggested that exercise can help improve VO2max for patients taking GLP-1 drugs, but these had poor controls and larger, well-designed studies are needed to bear that out. Also, foods consumed with more chews and smaller bites can help increase GLP-1 response and curb subsequent food intake in a meal. Ozempic is FDA-approved to help with blood sugar management in people with diabetes, while Wegovy is approved for weight loss in people who are overweight or struggle with obesity. The weight loss benefits of SGLT-2 inhibitors typically are less than those of GLP-1 agonists. GLP-1 receptor agonists can improve that. While these adverse effects are uncommon, they can be very serious; physicians must be vigilant for signs of pancreatitis and monitor kidney function among people taking GLP-1RA medications. GLP-1RA drugs were associated with significant benefits to neurological and behavioral health, with reduced risks of seizures and addiction to substances such as alcohol, cannabis, stimulants and opioids. Although reduced GLP-1 secretion has previously been associated with attenuated incretin effect in patients with type 2 diabetes, further research indicates that GLP-1 secretion in patients with type 2 diabetes does not differ from healthy subjects.

Here is my site - digestive fiber support